Transparency Guidelines
COVID-19
Who We Are
Our Industry
Resources
Login
Resources
Submissions
See all
PHARMAC Consultation: Proposal (dated 29 June 2021) to decline inactive funding applications
Medsafe Consultation: Medsafe Fees Review
PHARMAC Consultation: Revised Terms of Reference for CAC, PTAC and PTAC Sub-Committees and Associated PHARMAC Discussions document
Medsafe Consultation: Plan to update the New Zealand Code of Good Manufacturing Practice
PHARMAC Consultation: Proposal (dated 1 Oct 2020) to decline inactive funding applications 30 October 2020
Medsafe Consultation: Revisions to Part 10 of the GRTPNZ
PHARMAC Consultation: Proposal to modify PHARMAC’s approach to competitive procurement
Medsafe Consultation: Revisions to Part 8 of the GRTPNZ
Publications
See all
IQVIA A Decade of Modern Medicines: An International Comparison 2011 – 2020
Educational Whitepaper: Towards Best Practice in Consumer Involvement in Decisions about Funding Medicines in New Zealand
New Zealand's Medicines Landscape 2020/21
Public Perceptions of Healthcare, Pharmaceuticals and COVID-19 in New Zealand Key Findings of two National Online Surveys April 2021
Funding Medicines in New Zealand: Revision of the Medicines Waiting List to 30 April 2020
New Zealand's Medicines Landscape 2019/20
Public Perceptions of Medicines Funding in New Zealand - Key Findings of two National Online Surveys
Access to Medicines (AtoM 2) Report 2020
Media Releases
See all
International Medicines Report: New Zealand Past the Point of No Return?
Boring Budget 2021 reinforces two tier medicines access system in New Zealand
Medicines New Zealand supportive of Government’s PHARMAC Review assuming it is not a box-ticking exercise
Medicines New Zealand and the New Zealand Medical Association launch Transparency Initiative
EU export restrictions on COVID-19 vaccines may jeopardise global supply
PHARMAC Inquiry: “nothing should be off the table”
Collaborative Consultation on Medicines Policy Closes
Solutions for the Future: A New Medicines Landscape
